New York Hospitals Redirect Drug Savings

Hospitals are supposed to use 340B drug discounts to stretch scarce resources for poorer patients. But in New York, a new analysis says a lot of that money is ending up somewhere else — investment portfolios, contract staffing, and big revenue lines that are hard for the public to track. That matters because 340B has become a huge hidden subsidy inside the health system. And right now Albany is debating whether to protect and expand the way hospitals use it. ### What is 340B, exactly? 340B is a federal drug discount program created in 1992. Eligible hospitals and clinics can buy outpatient drugs at steep discounts — often 23% to 50% below list prices — and then get reimbursed by insurers at the usual rates. The spread becomes extra cash for the provider. The idea was simple: safety-net institutions would use that margin to serve more low-income and uninsured patients. But federal law does not tightly dictate how hospitals must spend the money, and public reporting is thin. (jamanetwork.com) ### What did the new New York analysis say? The March 19 analysis, by Lisa Grabert of Marquette University, argues New York hospitals in 340B are acting less like cash-strapped safety nets and more like organizations with a lucrative side business. It says participating hospitals had average revenue of $932 million, versus $423 million at non-340B hospitals, and held 42% more in stocks(jamanetwork.com)are shares were not meaningfully higher at 340B hospitals despite the larger revenue base. (betterhospitalsnow.org) ### Why are investments the part people notice? Because investments are the clearest sign that the money is not obviously flowing straight to patients. If a hospital says 340B keeps the lights on, that is one argument. If the same hospital is also building a much larger financial portfolio, critics see a gap between the p(betterhospitalsnow.org) like unrestricted margin. (betterhospitalsnow.org) ### What about contract labor? That is the second eyebrow-raiser. The analysis says New York 340B hospitals paid contract workers nearly double what they paid full-time employees on average. That does not prove misuse by itself — hospitals everywhere leaned harder on temporary staffing after the pandemic — but it does suggest the savings may be helping absorb expensive operating pressures rather than directly lowering patient costs or expanding free care. (betterhospitalsnow.org) ### Are there concrete examples behind the broader claim? Yes. Public tax filings already showed some giant pharmacy revenue streams at major downstate systems. Empire Center highlighted 2024 pharmacy-related revenue of about $873 million at NYU Langone, $571 million at Mount Sinai, $167 million at NewYork-Presbyterian, a(betterhospitalsnow.org)but it shows how large the channel has become. (empirecenter.org) ### Why is this flaring up now? Because New York lawmakers are considering S1913, the “340B prescription drug anti-discrimination act.” The bill would bar drugmakers and PBMs from restricting covered entities and contract pharmacies based on 340B participation. Supporters say hospitals need that protection to preserve a critical funding stream. Critics say locking in broader contract-pharmacy access without stronger transparency just protects a black box. (nysenate.gov) ### Don’t hospitals say 340B still helps patients? They do, and this is the real fight. Hospital advocates say 340B hospitals treat more Medicaid patients, deliver more uncompensated care, and use savings to support unprofitable services like trauma, behavioral health, translation, and transportation. A Senate HELP Committee report from 2025 also showed hospitals often fold 340B benefits into broader budg(nysenate.gov)whether the money helps hospitals. It is whether that is close enough to helping the intended patients. (340bhealth.org) ### What is the bottom line? The New York story is not just “hospitals made money.” Hospitals always juggle margins. The sharper question is whether a federal discount meant for vulnerable patients has turned into a lightly supervised revenue engine. Albany is being asked to protect that engine now. The catch is that lawmakers still do not have a clean line of sight into where the savings go.